Treatment incidence and patterns in children and adolescents with autism spectrum disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 15, Issue 4, 2005, Pages 671-681

  Witwer, Andrea ^a   Lecavalier, Luc ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CASEIN; CITALOPRAM; CLONIDINE; DEXAMPHETAMINE; FLUOXETINE; GLUTEN; GUANFACINE; LACTOSE; LITHIUM; METHYLPHENIDATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SECRETIN; SERTRALINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VITAMIN; ZIPRASIDONE;

ADAPTIVE BEHAVIOR; ADOLESCENT; ADULT; AGE; ARTICLE; AUTISM; BEHAVIOR DISORDER; CHILD; CONTROLLED STUDY; DIET THERAPY; DRUG USE; FEMALE; HUMAN; INTERPERSONAL COMMUNICATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PARENT; PREDICTION; SCHOOL; SOCIAL BEHAVIOR; UNITED STATES; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; AGE FACTORS; AUTISTIC DISORDER; BEHAVIOR; CHILD; CHILD, PRESCHOOL; DIET; DRUG UTILIZATION; FEMALE; HUMANS; MALE; OHIO; PARENTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; QUESTIONNAIRES; SCHOOLS; SOCIAL BEHAVIOR; VITAMINS;

EID: 26444595640     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2005.15.671     Document Type: Article

References (30)

1. Aman MG: Stimulant drugs in the developmental disabilities revisited. J Dev Phys Disabil 8:347-365, 1996.
2. Aman MG, Arnold LE, Armstrong SC: Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Ment Retard Dev Disabil Res Rev 5:279-285, 1999.
3. Aman MG, Lam KS, Collier-Crespin A: Prevalence and patterns of use among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord 33:527-534, 2003.
4. Aman MG, Lam KSL, Van Bourgondien ME: Medication patterns in patients with autism: Temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 15:116-126, 2005.
5. Aman MG, Langworthy KS: Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord 30:451-459, 2000.
6. Aman MG, Madrid A: Atypical antipsychotics in persons with developmental disabilities. Ment Retard Dev Disabil Res Rev 5:253-263, 1999.
7. Aman MG, Singh NN: Patterns of use, methodological considerations, measurement techniques, and future trends. In: Psychopharmacology of the Developmental Disabilities. Edited by Aman MG, Singh NN. New York, Spring-Verlag, 1988.
8. Aman MG, Tassé MJ, Rojahn J, Hammer D: The Nisonger CBRP: A child behavior rating form for children with developmental disabilities. Res Dev Disabil 17:41-57, 1996.
9. Aman MG, Van Bourgondien ME, Wolford PL, Sarphare G: Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Am Acad Child Adolesc Psychiatry 34:1672-1681, 1995.
10. Bruininks RH, Woodcock RW, Weatherman RF, Hill BK: Scales of Independent Behavior-Revised: Manual. Boston, Riverside Publishing, 1996.
11. Conners CK, Sparrow EP: Nootropics and foods. In: Practitioner's Guide to Psychoactive Drugs for Children and Adolescents. Edited by Werry JS, Aman MG. New York, Plenum Publishing, 1999, pp 413-432.
12. Gadow KD, DeVincent CJ, Azizian A: Psychiatric symptoms in preschool children with PDD and clinic and comparison samples. J Autism Dev Disord 34:379-393, 2004.
13. Gadow KD, DeVincent CJ, Pomeroy J, Azizian A: Comparison of DSM-IV symptoms in elementary school-aged children with PDD versus clinic and community samples. Autism In press.
14. Gillberg C, Stefenburg S: Outcome and prognostic factors in infantile autism and similar conditions: A population-based study of 46 cases followed through puberty. J Autism Dev Disord 17:273-287, 1987.
15. Hammer D, Lecavalier L: Successful models and demonstration projects in autism spectrum disorders. Columbus (OH), Ohio Department of Education, 2003.
16. Handen BL, Feldman HM, Lurier A, Murray PJ: Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 38:805-812, 1999.
17. Handen BL, Janosky J, McAuliffe S: Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD. J Abnorm Child Psychol 25:287-295, 1997.
18. Langwothy-Lam KS, Aman MG, Van Bourdondien ME: Prevalence and patterns of use of psychoactive medicines in individuals with autism on the Autism Society of North Carolina. J Child Adolesc Psychopharmacol 12:311-321, 2002.
19. Lecavalier L. Behavior and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics and empirical classification. J Autism Dev Disord, in press.
20. Lecavalier L, Aman MG: Rating instruments. In: Behavior Modification for Persons with Developmental Disabilities: Empirically Supported Treatments. Volume I. (pp. 160-189). Edited by Matson JL, Laud RB, Matson ML, Kingston, NY, National Association for the Dually Diagnosed, 2005.
21. Lecavalier L, Aman MG, Hammer D, Stoica W, Matthews GL: Factor analysis of Nisonger Child Behavior Rating Form in children with autism spectrum disorders. J Autism Dev Disord 34, In press.
22. Martin A, Scahill L, Klin A, Volkmar FR: Higher-functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 38:923-931, 1999.
23. Metz B, Mulick JA, Butter E: Autism: A late 20th century fad magnet. In: Controversial therapies for developmental disabilities: Fad, fashion, and science in professional practice (pp. 237-263). Edited by Jacobson JW, Foxx RM, Mulick. JA. Hillsdale, NJ, Lawrence Erlbaum Associates, 2005.
24. Millward C, Ferriter M, Calver S, Connell-Jones G: Gluten- and casein-free diets for autism spectrum disorder. The Cochrane Database of systematic Reviews, http://gateway.ut.ovid.com/gw2/ovid-web.cgi, 2004.
25. Nye C, Brice A: Combined vitamin B6-magnesium treatment in autism spectrum disorder. [Review]. The Cochrane Database of Systematic Reviews. The Cochrane Library, 2004. http://gateway. ut.ovid.com/gw2/ovidweb.cgi, 2004.
26. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: A double-blind, placebo-controlled trial of risperidone in children with autistic disorder. N Engl J Med 347:314-321, 2002.
27. Spreat S, Conroy J: Use of psychotropic medications for persons with mental retardation who live in Oklahoma nursing homes. Psychiatr Serv 49:510-512, 1998.
28. Tonge BJ, Einfeld SL: Psychopathology and intellectual disability: The Australian child to adult longitudinal study. In: International Review of Research in Mental Retardation. Edited by Glidden LM. San Diego, (CA), Academic Press, 2003, pp 61-91.
29. Valdovinos MG, Schroeder SR, Kim G: Prevalence and correlates of psychotropic medication use among adults with developmental disabilities: 1970-2000. In: International Review of Research in Mental Retardation. Edited by Glidden LM. San Diego, (CA), Academic Press, 2003, pp 175-220.
30. Wolf L, Goldberg B: Autistic children grow up: An eight- to twenty-four-year follow-up study. Can J Psychiatry 31:550-556, 1986.